Skip to content

An single center randomized controlled trial of saturated saline thermotherapy combined with imiquimote cream in the treatment of refractory multiple warts of hands and feet

An single center randomized controlled trial of saturated saline thermotherapy combined with imiquimote cream in the treatment of refractory multiple warts of hands and feet

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099737
Enrollment
Unknown
Registered
2025-03-27
Start date
2025-03-27
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable multiple warts of hands and feet caused by HPV infection

Interventions

Experimental group:Thermotherapy combined with topical imiquimod cream.
Control group:Imiquimod cream for topical use only.

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-70 years old with multiple warts of hands and feet caused by HPV infection (number of warts >=5) who have received any treatment or combination treatment such as liquid nitrogen cryotherapy, laser therapy or local injection therapy for at least 3 times in the past, and whose rash still does not subside significantly or relapsed were treated with 5% imiquimote cream.

Exclusion criteria

Exclusion criteria: 1.Received local or systemic immunotherapy (including thermotherapy) or topical imiquimod cream within the past three months; 2.Physical therapy such as liquid nitrogen freezing within the past month; 3.Severely immunosuppressed patients (such as those with HIV infection, organ or bone marrow transplantation); 4.Patients with concurrent systemic use of immunosuppressants such as glucocorticoids.

Design outcomes

Primary

MeasureTime frame
Total response rate of all groups at week 8;

Secondary

MeasureTime frame
The number and area of warts changed from baseline at week 8;Recurrence rate at week 24;Overall security for all groups at week 8;

Countries

China

Contacts

Public ContactXiaoyan Liu

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

hzliuxiaoyan@126.com+86 13957162809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026